Profile data is unavailable for this security.
About the company
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The Company has trademarked its repurposed Exenatide as Presendin. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.
- Revenue in AUD (TTM)473.31k
- Net income in AUD-835.91k
- Incorporated2019
- Employees--
- LocationInvex Therapeutics LtdLevel 2, 38 Rowland St, SubiacoPERTH 6008AustraliaAUS
- Websitehttps://invextherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPH Global Ltd | 352.38k | -1.49m | 4.71m | 31.00 | -- | -- | -- | 13.36 | -0.0026 | -0.0026 | 0.0006 | -0.0014 | 0.8548 | 3.49 | 2.27 | -- | -360.76 | -76.32 | -- | -214.32 | 6.86 | 17.08 | -422.04 | -156.56 | 0.1995 | -43.14 | -- | -- | 220.43 | -13.56 | 24.87 | -- | -- | -- |
| Argent BioPharma Ltd | 180.56k | -17.84m | 4.87m | -- | -- | -- | -- | 26.96 | -0.3292 | -0.3292 | 0.0032 | -0.1196 | 0.0272 | 0.2721 | 0.4238 | -- | -269.25 | -135.49 | -- | -380.42 | 24.06 | -45.51 | -9,882.75 | -764.45 | 0.1752 | -321.38 | -- | -- | -79.74 | -38.66 | -1.79 | -- | -70.28 | -- |
| Chimeric Therapeutics Ltd | 3.97m | -10.43m | 6.63m | -- | -- | 1.61 | -- | 1.67 | -0.007 | -0.007 | 0.0028 | 0.0009 | 0.2154 | -- | 1.73 | -- | -56.62 | -66.67 | -171.92 | -112.02 | 78.66 | -- | -262.83 | -2,013.07 | -- | -62.30 | 0.7162 | -- | -- | -- | 16.76 | -- | -- | -- |
| Invion Ltd | 0.00 | -8.81m | 6.85m | 8.00 | -- | 0.823 | -- | -- | -0.1183 | -0.1183 | 0.00 | 0.0972 | 0.00 | -- | -- | -- | -70.63 | -29.16 | -77.64 | -30.88 | -- | -- | -- | -147.34 | -- | -- | 0.00 | -- | -100.00 | -- | -56.50 | -- | -- | -- |
| Nexalis Therapeutics Ltd | 837.55k | -1.33m | 7.09m | -- | -- | -- | -- | 8.46 | -0.006 | -0.006 | 0.0037 | -0.0041 | 0.8301 | -- | 2.50 | -- | -131.43 | -73.85 | -- | -100.32 | -- | -- | -158.33 | -369.19 | -- | -- | -- | -- | -66.38 | 21.67 | 16.21 | -- | -- | -- |
| Vectus Biosystems Ltd | 18.77k | -1.78m | 7.21m | -- | -- | -- | -- | 384.31 | -0.0334 | -0.0334 | 0.0004 | -0.0048 | 0.0134 | -- | 0.0266 | -- | -126.57 | -79.19 | -247.24 | -189.44 | -- | -- | -9,468.62 | -10,165.01 | 0.9301 | -554.06 | -- | -- | -75.58 | 73.61 | 23.99 | -- | -- | -- |
| Percheron Therapeutics Ltd | 371.10k | -14.92m | 7.61m | 8.00 | -- | 0.7609 | -- | 20.51 | -0.0149 | -0.0149 | 0.0004 | 0.0092 | 0.0275 | -- | 0.2824 | -- | -110.67 | -79.28 | -153.98 | -96.61 | -- | -- | -4,021.00 | -3,694.96 | -- | -1,093.50 | 0.0026 | -- | -39.71 | 64.80 | -25.19 | -- | -6.74 | -- |
| Biotron Ltd | 0.00 | -318.57k | 8.11m | 4.00 | -- | 7.21 | -- | -- | -0.0004 | -0.0004 | 0.00 | 0.0004 | 0.00 | -- | -- | -- | -43.23 | -86.63 | -206.95 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 90.73 | -- | -- | -- |
| Invex Therapeutics Ltd | 473.31k | -835.91k | 9.39m | -- | -- | 2.07 | -- | 19.85 | -0.0111 | -0.0111 | 0.0063 | 0.0605 | 0.0894 | -- | 5.09 | -- | -15.79 | -15.04 | -16.83 | -15.74 | -- | -- | -176.61 | -419.12 | -- | -- | 0.00 | -- | -72.92 | 22.74 | 70.95 | -- | -- | -- |
| Adalta Ltd | 695.66k | -4.50m | 10.20m | -- | -- | -- | -- | 14.66 | -0.0059 | -0.0059 | 0.0009 | -0.0005 | 0.1804 | -- | 0.4992 | -- | -116.72 | -70.41 | -216.60 | -126.24 | -- | -- | -647.19 | -207.18 | -- | -75.41 | 1.51 | -- | -61.02 | -28.97 | 16.33 | -- | -- | -- |
| BPH Energy Ltd | 914.02k | -1.21m | 10.83m | 2.00k | -- | 0.2569 | -- | 11.85 | -0.001 | -0.001 | 0.0008 | 0.0311 | 0.0235 | -- | 8.56 | -- | -3.10 | 9.05 | -3.15 | 9.45 | -- | -- | -132.17 | 431.04 | -- | -0.8233 | 0.0022 | -- | -0.8344 | 28.34 | 48.93 | 43.33 | -- | -- |
| Imagion Biosystems Ltd | 1.06m | -2.20m | 11.28m | -- | -- | -- | -- | 10.69 | -0.0177 | -0.0177 | 0.0082 | -0.0192 | 1.45 | -- | 1,173.13 | -- | -302.58 | -76.63 | -- | -102.36 | -- | -- | -208.52 | -911.24 | -- | -0.7972 | -- | -- | -18.54 | 22.02 | 83.43 | -- | -- | -- |
| Cambium Bio Ltd | 670.05k | -3.84m | 12.06m | -- | -- | 5.23 | -- | 18.00 | -0.3489 | -0.3489 | 0.0596 | 0.1004 | 0.1498 | -- | 2.58 | -- | -85.96 | -41.30 | -146.56 | -75.44 | 70.04 | -- | -573.73 | -118.71 | -- | -- | 0.2082 | -- | 419.43 | -16.63 | -70.42 | -- | -- | -- |
